Literature DB >> 19604728

Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation.

Martin Roderfeld1, Timo Rath, Richard Schulz, Werner Seeger, Annette Tschuschner, Jürgen Graf, Elke Roeb.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) virtually degrade all components of the extracellular matrix and are mainly expressed in tissues following inflammation or remodeling. Increased expression of certain MMPs in sputum and bronchoalveolar lavage of patients with cystic fibrosis (CF) is related to impaired lung function. We investigated whether a panel of serum MMPs is associated with both, impairment of pulmonary function and occurrence of pulmonary exacerbations (PEx) in adult patients with CF.
METHODS: Serum concentrations of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, and TIMP-1 were determined by ELISA in 54 adult CF patients. PEx was defined based on a score established by Rosenfeld in 2001. MMP-1, MMP-8, MMP-9 and TIMP-1 were assessed in 7 CF patients with PEx before and after systemic antibiotic therapy.
RESULTS: Of the 54 CF patients, PEx was diagnosed in 16 different CF patients. Compared to healthy controls, MMP-1, MMP-8, and MMP-9, serum levels were elevated in CF patients and correlated with PEx. MMP-8 expression was associated with impaired lung function. For MMP-2, we observed a decreased expression and an association of MMP-2 decline with PEx. Antibiotic treatment of CF patients with PEx led to a decrease of MMP-1, MMP-8 and active MMP-9 protein concentration.
CONCLUSIONS: Increased serum expression of certain MMPs is associated with occurrence of PEx and impaired lung function in CF. Hence, these MMPs might serve as surrogate markers for PEx.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19604728     DOI: 10.1016/j.jcf.2009.06.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  11 in total

1.  Influence of MMP-8 promoter polymorphism in early osseointegrated implant failure.

Authors:  F R Costa-Junior; C C Alvim-Pereira; F Alvim-Pereira; P C Trevilatto; A P de Souza; Maria Cristina L G Santos
Journal:  Clin Oral Investig       Date:  2012-03-02       Impact factor: 3.573

Review 2.  The role of matrix metalloproteinases in cystic fibrosis lung disease.

Authors:  A Gaggar; A Hector; P E Bratcher; M A Mall; M Griese; D Hartl
Journal:  Eur Respir J       Date:  2011-01-13       Impact factor: 16.671

3.  Association of MMP-8 polymorphisms with tendinopathy of the primary posterior tibial tendon: a pilot study.

Authors:  Alexandre Leme Godoy-Santos; Rafael Trevisan; Túlio Diniz Fernandes; Maria Cristina L G dos Santos
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  Potential of anti-inflammatory treatment for cystic fibrosis lung disease.

Authors:  Jennifer L Taylor-Cousar; Kelsey A Von Kessel; Robert Young; David P Nichols
Journal:  J Inflamm Res       Date:  2010-08-10

5.  Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations.

Authors:  Ashutosh Sharma; Gordon Kirkpatrick; Virginia Chen; Kate Skolnik; Zsuzsanna Hollander; Pearce Wilcox; Bradley S Quon
Journal:  PLoS One       Date:  2017-02-08       Impact factor: 3.240

6.  MMP-9 cleaves SP-D and abrogates its innate immune functions in vitro.

Authors:  Preston E Bratcher; Nathaniel M Weathington; Heidi J Nick; Patricia L Jackson; Robert J Snelgrove; Amit Gaggar
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

7.  IP-10 is a potential biomarker of cystic fibrosis acute pulmonary exacerbations.

Authors:  George M Solomon; Carla Frederick; Shaoyan Zhang; Amit Gaggar; Tom Harris; Bradford A Woodworth; Chad Steele; Steven M Rowe
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

8.  Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic fibrosis.

Authors:  Bradley S Quon; David A Ngan; Pearce G Wilcox; S F Paul Man; Don D Sin
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

9.  Serum matrix metalloproteinase levels in patients exposed to sulfur mustard.

Authors:  Majid Shohrati; Reza Haji Hosseini; Malek Ashtar Esfandiari; Nastaran Najafian; Bita Najafian; Abbas Golbedagh
Journal:  Iran Red Crescent Med J       Date:  2014-03-05       Impact factor: 0.611

10.  Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis.

Authors:  Rosa Maria Girón-Moreno; José L Justicia; Sara Yamamoto; Claudia Valenzuela; Carolina Cisneros; Rosa Mar Gómez-Punter; Gilda Fernandes-Vasconcelos; Julio Ancochea
Journal:  BMC Pulm Med       Date:  2014-09-23       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.